Alembic Pharmaceuticals has announced the formal incorporation of a new subsidiary, Alembic Lifesciences Philippines Inc., in the Philippines. This strategic move is designed to tap into new business opportunities within the region. The newly formed entity will focus on promoting, selling, and distributing the company’s pharmaceutical products. The parent company currently maintains a 99.99% shareholding in this new international venture, signaling a focused effort to bolster its global footprint.
Strategic Global Expansion
On April 22, 2026, Alembic Pharmaceuticals confirmed the establishment of its latest subsidiary, Alembic Lifesciences Philippines Inc. This incorporation marks a deliberate step toward expanding the company’s operational reach into the Philippines. By establishing a local entity, the company aims to streamline its distribution channels and strengthen its presence in the local pharmaceutical market.
Financial and Structural Details
The newly formed subsidiary has been incorporated with a total share capital of 12,000,000 Philippine Pesos. This capital is divided into 1,200,000 shares, with a face value of 10 Philippine Pesos each. Alembic Pharmaceuticals holds a 99.99% controlling interest in the entity. As the subsidiary is a newly incorporated firm, its current turnover is nil, as it has yet to commence formal business operations.
Focus on Business Growth
The primary objective behind this incorporation is to explore and capture new business opportunities within the Philippine geography. The subsidiary is mandated to manage the promotion, sale, and distribution of the company’s diverse pharmaceutical product portfolio. This expansion is part of a broader initiative by the company to enhance its international revenue streams through targeted regional growth.
Source: BSE
